Exercise, Inflammation, and Breast Cancer: What the Data Show

Exercise can improve health before and after a breast cancer diagnosis, but the inflammation story is narrower than the usual wellness pitch. In women at elevated breast cancer risk, exercise lowered two inflammatory cytokines—TNF-α and IL-6—in a meta-analysis of trials. In breast cancer survivors, the most responsive marker was leptin, particularly in programs that produced weight loss. Those are useful findings. They do not prove that every workout prevents cancer, lowers recurrence, or fixes every inflammatory marker.

The distinction matters because inflammation is a plausible route through which physical activity could affect breast cancer biology. It is also easy to turn a plausible route into a certainty with one overconfident sentence. The human evidence supports a more specific conclusion: regular activity can change selected circulating biomarkers, while weight loss appears central to the recurrence signal observed in survivor trials.

Before diagnosis: exercise lowers TNF-α and IL-6, not every marker

Swain et al.'s 2023 systematic review and meta-analysis included 40 studies, 23 of them parallel-group randomized controlled trials, in women at breast cancer risk. Interventions lasted a median of 16 weeks and included aerobic, resistance, and combined training.

The pooled results support biomarker-specific effects. Exercise reduced TNF-α by a standardized mean difference (SMD) of -0.63 (95% CI, -1.04 to -0.22; eight studies; 564 participants) and IL-6 by an SMD of -0.55 (95% CI, -0.97 to -0.13; 11 studies; 895 participants). Both confidence intervals exclude zero, and the authors rated both findings moderate certainty.

That does not mean exercise reliably lowers the inflammatory panel on a standard lab report. C-reactive protein (CRP), the marker clinicians use most often, fell by an SMD of -0.27, but the 95% CI ranged from -0.62 to 0.08 across 12 studies and 1,210 participants. The result was not statistically significant and received a low GRADE rating. Leptin also did not reach statistical significance in this population: SMD -0.50, 95% CI -1.10 to 0.09, across four studies and 586 participants.

Most revealing, adiponectin did not move. The pooled estimate was SMD +0.01 (95% CI, -0.14 to 0.17), with high-certainty evidence. Adiponectin often appears in exercise-and-cancer explanations as the helpful adipokine that exercise supposedly raises. This analysis does not support that claim in women at breast cancer risk. A precise null is still a result.

Several cytokine outcomes showed meaningful between-study heterogeneity, which lowered certainty for most non-adiponectin estimates. Differences in menopausal status, exercise type, duration, and participant characteristics may matter, but the available pooled evidence cannot tell a reader which routine works best for which subgroup. It also does not identify a minimum weekly exercise dose that changes TNF-α or IL-6.

After treatment: leptin becomes the more responsive signal

The pattern shifts in breast cancer survivors. Bruinsma et al.'s 2022 systematic review and meta-analysis examined diet- and exercise-induced weight-loss interventions in survivors and identified leptin as the most consistently responsive inflammatory biomarker. Across included interventions, leptin declined by a weighted mean difference of 5.66 ng/mL.

That figure cannot be numerically compared with the prevention meta-analysis's leptin SMD. One measure is an absolute concentration and the other is standardized to variability within studies. Still, the contrast is clinically useful: leptin showed the clearest intervention response in the survivor literature, while the prevention analysis did not find a statistically significant leptin reduction in generally at-risk women.

The reasons may include differences in baseline adiposity, treatment history, interventions, and weight change. They are not proof that cancer treatment itself creates a specific leptin mechanism. What the evidence directly shows is a different biomarker hierarchy across the two populations.

Weight loss, rather than diet quality alone, tracks with the recurrence result

The most patient-relevant outcome in this evidence base is recurrence, and it comes with an important qualifier. Bruinsma et al. discussed two dietary trials with sharply different weight-change results. In WINS, a caloric-restriction intervention produced 2.4 kg of weight loss and was associated with a recurrence hazard ratio of 0.76 (95% CI, 0.60 to 0.98). In WHEL, an isocaloric dietary intervention produced a net 1.1 kg weight gain and showed no recurrence benefit.

This contrast supports weight loss as a likely operative feature of the beneficial intervention, rather than dietary composition by itself. It does not prove that exercise alone, without caloric restriction or measurable weight loss, produces the same recurrence reduction. Nor does a hazard ratio provide an absolute recurrence difference; that depends on a survivor's baseline risk and is not reported here.

For survivors with excess adiposity, the practical target is therefore measurable, clinically supervised weight reduction when appropriate—not a particular macronutrient identity badge. Exercise remains valuable because it can help create and maintain an energy deficit while improving fitness and physical function. The recurrence finding itself, however, came from a dietary caloric-restriction trial, not from an exercise-only trial.

Leptin may matter biologically, but the tumor mechanism remains unproven

A 2025 dietary intervention in people with metastatic breast cancer adds a biologically interesting observation. Rieth et al. reported that a whole-food plant-based intervention coincided with reductions in leptin, VEGF-C, an angiogenesis marker, and CA15-3, a tumor-burden marker. The co-reductions fit the hypothesis that leptin participates in tumor-related signaling.

They do not establish that lowering leptin caused lower VEGF-C or CA15-3, nor that exercise-driven leptin reductions would reproduce these changes. This was a dietary intervention in advanced disease, not an exercise trial in early-stage survivors or a prevention study. Biomarkers can be useful clues; they are not a substitute for recurrence or survival outcomes.

What type of exercise should survivors choose?

Exercise has benefits beyond cytokines and adipokines. A 2025 meta-analysis of randomized trials of HIIT in breast cancer survivors found clinically meaningful improvements across multiple outcomes. The available report does not provide biomarker-specific effect estimates for TNF-α, IL-6, CRP, or leptin, so it cannot establish that HIIT beats moderate-intensity training for inflammation.

Combined aerobic and resistance training also has direct survivor-specific evidence. In a randomized trial, Dieli-Conwright et al. found that this approach altered circulating MOTS-c, a mitochondrial-derived peptide involved in metabolic and stress signaling, in Hispanic and non-Hispanic White breast cancer survivors. The clinical meaning of a MOTS-c change for cancer outcomes remains exploratory.

Outside cancer care, a 2024 meta-analysis in sedentary adults found that combined training improved glucose metabolism and inflammatory-marker profiles. That broadens the case for combining aerobic and resistance work, but it does not answer cancer-specific questions about recurrence or the optimal training dose.

What this means for fatigue and daily decisions

Exercise programs can improve several survivor outcomes, and fatigue often belongs in that wider rehabilitation conversation. The evidence summarized here does not show that TNF-α, IL-6, or leptin changes cause fatigue improvement, nor does it define an inflammation-based exercise prescription for fatigue. Treat that proposed mechanism as a research question, not a settled explanation.

For women at breast cancer risk, the best-supported inflammatory changes are lower TNF-α and IL-6 after regular exercise. For survivors, leptin reduction and actual weight loss deserve more attention than claims about adiponectin or a universal anti-inflammatory effect.

The evidence supports exercise as part of breast cancer prevention and survivorship care, with the usual need to adapt training to symptoms, treatment effects, and clinical guidance. Its anti-inflammatory effects are real but selective. Adiponectin does not appear to be the mechanism in prevention studies, CRP has not shown a statistically significant pooled reduction there, and the recurrence signal is tied to weight loss achieved through caloric restriction. Those limits make the conclusion more useful, not less: move regularly, build strength, and when weight loss is medically appropriate, measure whether the plan actually produces it.